Promising transcatheter MViV outcomes | AI-powered electrocardiograms | Another COVID-related EUA for Abiomed

The overall procedural technical success rate, researchers reported, was 96.8%.

The study, published in Circulation: Arrhythmia and Electrophysiology, included data from more than 1,600 patients who presented at the ED with shortness of breath. 

This is the second EUA for Abiomed's Impella heart pumps during the COVID-19 pandemic.  

As the COVID-19 pandemic continues, researchers have been forced to put important projects on hold—and it’s unclear when things will return to normal.

In the last six days, multiple White House experts have all emphasized they don’t support the use of hydroxychloroquine as a treatment option for COVID-19. 

Differentiating between actual signs of a COVID-19 infection and standard cardiac complications can be especially difficult.

In February and March 2020, the inevitable happened: COVID-19 came to the United States, hitting the country’s healthcare system like a 10-pound sledgehammer. 

The Centers for Medicare and Medicaid Services recently unveiled its proposed Medicare Physician Fee Schedule, which is set to take effect on Jan. 1.

Pandemic forecasting models aren’t hard to find of late, but a new one combines epidemiological expertise from a top-three medical school with AI knowhow from one of big tech’s biggest.